Activity of systemic therapies after cabozantinib (CABO) in patients (pts) with metastatic renal cell carcinoma (mRCC)

被引：1
|
作者：
Cerbone, L. [1 ]
Di Nunno, V. [2 ]
Carril, L. [1 ]
Benchimol-Zouari, A. [1 ]
Flippot, R. [1 ]
Silva, C. Alves Costa [1 ]
Colomba-Blameble, E. [1 ]
Guida, A. [3 ]
Derosa, L. [1 ]
Escudier, B. [1 ]
Albiges, L. [1 ]
机构：
[1] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[2] Osped Bellaria, Oncol Med, Bologna, Italy
[3] Osped Santa Chiara Terni, Med & Traslat Oncol, Terni, Italy
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.815
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
743P
引用
收藏
页码：S577 / S577
页数：1
相关论文
共 50 条
  • [31] Cabozantinib in metastatic renal cell carcinoma (mRCC): Real world experience from the UK
    de Liano, Alfonso Gomez
    Venugopal, Balaji
    Fife, Kate
    Khasti, Luma
    Symeonides, Stefan N.
    Pettinger, Claire
    Powles, Thomas
    Rudman, Sarah Maria
    Vasudev, Naveen
    Boleti, Ekaterini
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC)
    Kao, Chester
    George, Daniel J.
    Zhang, Tian
    ONCOLOGIST, 2021, 26 (03): : E508 - E511
  • [33] Skin toxicity of sunitinib: Prospective analysis in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Billemont, B.
    Barete, S.
    Meric, J. B.
    Moguelet, P.
    Frances, C.
    Chosidow, O.
    Goldwasser, F.
    Rixe, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] Characterizing fatigue associated with sunitinib (SU) in patients (pts) with metastatic renal cell carcinoma (mRCC).
    Cella, David
    Davis, Mellar P.
    Bushmakin, Andrew G.
    Cappelleri, Joseph C.
    Hahn, Elizabeth A.
    Korytowsky, Beata
    Bhattacharyya, Helen
    Sandin, Rickard
    Beaumont, Jennifer L.
    Matczak, Ewa
    Motzer, Robert John
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Phase II study of lenalidomide in patients (pts.) with metastatic renal cell carcinoma (MRCC).
    Choueiri, T. K.
    Dreicer, R.
    Rini, B. I.
    Elson, P.
    Garcia, J.
    Mekhail, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 226S - 226S
  • [36] External validation of a sunitinib prognostic nomogram in patients (pts) with metastatic renal cell carcinoma (mRCC).
    Yu, Changhong
    Kattan, Michael W.
    Hutson, Thomas E.
    Hudes, Gary R.
    Yuan, Jinyu
    Valota, Olga
    Motzer, Robert John
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] Outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with cabozantinib (CABO) after lenvatinib plus pembrolizumab (LEN plus PEM).
    Haro-Silerio, Jaime Ivan
    Johns, Andrew
    Moussa, Mohammad Jad
    Wang, Mindy
    Wang, Emily
    Kovitz, Craig A.
    Campbell, Matthew T.
    Jonasch, Eric
    Shah, Amishi Yogesh
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 433 - 433
  • [38] Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial.
    Ebrahimi, Hedyeh
    Meza, Luis A.
    Lee, Keehoon
    Malhotra, Jasnoor
    Alcantara, Marice
    Zengin, Zeynep Busra
    Dizman, Nazli
    Govindarajan, Ameish
    Hsu, Joann
    Llamas-Quitiquit, Marian
    Chawla, Neal Shiv
    Castro, Daniela V.
    Mercier, Benjamin D.
    Liu, Sandy
    Chehrazi-Raffle, Alex
    Dorff, Tanya B.
    Frankel, Paul Henry
    Li, Xiaochen
    Pal, Sumanta Kumar
    Tripathi, Abhishek
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [39] Patients (Pts) with Metastatic Renal Cell Carcinoma (mRCC) Receiving Angiogenesis Inhibitor (AI) Therapies: Treatment Efficacy and Safety in Clinical Practice
    McDermott, David
    Choueiri, Toni K.
    Clement, Jessica
    Brick, Ashley J.
    Kwabi, Christabel
    Shah, Karishma
    Antras, Lucia
    Jayawant, Sujata S.
    Wang, Si-Tien
    Luka, Andi
    Duh, Mei Sheng
    Neary, Maureen
    Oh, William K.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S111 - S112
  • [40] PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC) RECEIVING ANGIOGENESIS INHIBITOR (AIS) THERAPIES: TREATMENT EFFICACY AND SAFETY IN CLINICAL PRACTICE
    McDermott, D.
    Choueiri, T. K.
    Clement, J.
    Brick, A. J.
    Kwabi, C.
    Shah, K.
    Banerjee, A.
    Duh, M. S.
    Neary, M. P.
    Oh, W. K.
    ANNALS OF ONCOLOGY, 2008, 19 : 190 - 191
12345